Estimated parameter values for Ki for DDI cases
The table only includes DDI cases for which the inclusion of substrate metabolite information improved the geometric CV (Fig 3A). Parameter estimates represent summary statistics of 30 parameter sets reproducing concentration–time profiles (low SSlog,time). Refer to Table 2 for details of DDI information with corresponding ID number.
| Inhibitors | Substrates | Isoforms for Parameters | ID Number | Geometric Mean (μM) | Geometric CV (%) |
|---|---|---|---|---|---|
| Fluconazole | Fentanyl | CYP3A | 4 | 7.73 | 14.9 |
| Flurbiprofen | CYP2C9 | 6 | 17 | 4.64 | |
| 7 | 19.9 | 5.51 | |||
| Fluoxetine | Desipramine | CYP2D6 | 2a | 0.000195 | 14.5 |
| 3b | 0.000127 | 5.09 | |||
| Imipramine | 9a | 0.000177 | 7.9 | ||
| 10b | 0.000149 | 4.17 | |||
| Itraconazole | Oxycodone | CYP3A | 22 | 0.000115 | 7.67 |
| Ropivacaine | 24 | 0.000103 | 3.45 | ||
| Quinidine | Hydrocodone | CYP2D6 | 8 | 0.0000977 | 37.4 |
| Oxycodone | 20 | 0.000552 | 41.8 | ||
| Voriconazole | Oxycodone | CYP3A | 5 | 1.71 | 47.1 |
| 21 | 0.535 | 17 |